ホーム > 市場調査レポート > 医薬品

がん

市場調査レポート

商品コード

1498717

がんのガンマ・デルタT細胞治療の世界市場：市場の機会と臨床試験の洞察（2030年）

Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030

出版日: 2024年06月01日 | 発行: KuicK Research

| ページ情報: 英文 240 Pages | 納期: 即日から翌営業日

価格

PDF (Single User License)

USD 3,000 427,620円

レポートPDFを1名のみがご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは出来ません。 PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi-User License)

USD 6,000 855,240円

レポートPDFを貴社内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=142.54円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

未来型T細胞による免疫療法ががんの治療領域を席巻して久しいですが、他の最先端の治療法を開発することで、がん免疫療法の領域を広げることが求められています。しかし、それにもかかわらず、ガンマ・デルタT細胞、アルファ・ベータT細胞など、他のT細胞レセプターの発見につながっています。続いて、ガンマ・デルタT細胞に基づく免疫療法が発見され、ガンマ・デルタT細胞に基づく免疫療法を開発することが、ウイルス感染、自己免疫、炎症を含む他の疾患とともに、がんに対する革新的な治療を提供する一助となることがさらに現実的になっています。

ガンマ・デルタT細胞をベースとする免疫療法の世界の臨床導線は30品目（2024年6月現在）で構成され、そのうちの数品目は前臨床段階にあり、この分野の研究開発と技術進歩の大部分は米国と中国地域で進行中です。とはいえ、がんやその他の病気を治療する薬剤はまだ商業市場に浸透していません。しかし、1つの薬剤が承認され次第、他のガンマ・デルタT細胞ベースの免疫療法が市場に投入され、数百万米ドル規模の市場になる可能性が迫っています。

ガンマ・デルタT細胞ベースの免疫療法市場の成長を後押しする戦略的原動力の一つは、前臨床試験と臨床試験の増加です。過去10年間、世界のガンマ・デルタT細胞ベースの免疫療法市場は、いくつかの新規かつ革新的で先進的な競合企業の開発が促進されました。例えば、米国の臨床段階にあるバイオテクノロジー企業Acepodia Biotechは、PD-L1を発現する固形腫瘍とEGFRを発現する腫瘍を治療するために、ACE1708とACE2016の2つの競合薬を開発しました。

当レポートでは、世界のがんのガンマ・デルタT細胞治療市場について調査し、市場の概要とともに、癌治療における役割、地域別動向、臨床試験動向、および市場に参入する企業の競合動向などを提供しています。

List of Tables

Table 3-1: Candidates with Regulatory Designations
Table 6-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2024-2030
Table 6-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2024-2030
Table 6-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2024-2030
Table 6-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2024-2030
Table 6-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Leukemia, 2024-2030
Table 7-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2024-2030
Table 7-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2024-2030
Table 7-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2024-2030
Table 7-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2024-2030
Table 7-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Lung Cancer, 2024-2030
Table 8-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2024-2030
Table 8-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2024-2030
Table 8-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2024-2030
Table 8-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2024-2030
Table 8-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Breast Cancer, 2024-2030
Table 9-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2024-2030
Table 9-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2024-2030
Table 9-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2024-2030
Table 9-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2024-2030
Table 9-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Colorectal Cancer, 2024-2030
Table 10-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2024-2030
Table 10-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2024-2030
Table 10-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2024-2030
Table 10-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2024-2030
Table 10-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Pancreatic Cancer, 2024-2030
Table 11-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Lymphoma , 2024-2030
Table 11-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Lymphoma , 2024-2030
Table 11-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Lymphoma, 2024-2030
Table 11-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Lymphoma , 2024-2030
Table 11-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Lymphoma , 2024-2030
Table 12-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Brain Tumors, 2024-2030
Table 12-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Brain Tumors, 2024-2030
Table 12-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Brain Tumors, 2024-2030
Table 12-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Brain Tumors , 2024-2030
Table 12-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Brain Tumors , 2024-2030
Table 13-1: Global - Estimated Adoption Rate of Gamma Delta T Cell in Head & Neck Cancers, 2024-2030
Table 13-2: US - Estimated Adoption Rate of Gamma Delta T Cell in Head & Neck Cancers, 2024-2030
Table 13-3: Europe - Estimated Adoption Rate of Gamma Delta T Cell in Head & Neck Cancer, 2024-2030
Table 13-4: China - Estimated Adoption Rate of Gamma Delta T Cell in Head & Neck Cancers, 2024-2030
Table 13-5: Japan - Estimated Adoption Rate of Gamma Delta T Cell in Head & Neck Cancer, 2024-2030
Table 15-1: Ongoing Preclinical & Clinical Trials for Combination of Gamma Delta T Cell Therapy

List of Figures

Figure 1-1: History of T cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 1-4: Limitation of CAR T Cell Therapy
Figure 1-5: Limitations of TIL
Figure 1-6: Limitations of Monoclonal Antibodies
Figure 1-7: Drawbacks of Chemotherapeutic Drugs
Figure 2-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 2-2: Antigen Presentation Functions of Gamma Delta T-Cells
Figure 2-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 2-4: Gamma Delta T Cell Bispecific Antibodies - Mechanism of Action
Figure 2-5: Functional Advantages of Gamma-Delta T Cells for CAR T Cancer Therapy
Figure 2-6: CAR Gamma-Delta T Cells - Mechanism of Action
Figure 3-1: Global - Cell Therapy Market (US$ Billion), 2024 - 2030
Figure 3-2: Global - Gamma Delta T Cell Therapy Market Opportunity by 1% of Total Cell Therapy Market (US$ Billion), 2024-2030
Figure 3-3: Global - Gamma Delta T Cell Therapy Market Opportunity by 2% of Total Cell Therapy Market (US$ Billion), 2024-2030
Figure 3-4: Global - Gamma Delta T Cell Therapy Market Opportunity by 3% of Total Cell Therapy Market (US$ Billion), 2024-2030
Figure 3-5: Global - Gamma Delta T Cell Therapy Market Opportunity by 4% of Total Cell Therapy Market (US$ Billion), 2024-2030
Figure 3-6: Global - Gamma Delta T Cell Therapy Market Opportunity by 5% of Total Cell Therapy Market (US$ Billion), 2024-2030
Figure 3-7: Global - Gamma Delta T Cell Therapy Market Opportunity by 6% of Total Cell Therapy Market (US$ Billion), 2024-2030
Figure 3-8: Global - Gamma Delta T Cell Therapy Market Opportunity by 7% of Total Cell Therapy Market (US$ Billion), 2024-2030
Figure 3-9: Global - Gamma Delta T Cell Therapy Market Opportunity by 8% of Total Cell Therapy Market (US$ Billion), 2024-2030
Figure 3-10: Global - Gamma Delta T Cell Therapy Market Opportunity by 9% of Total Cell Therapy Market (US$ Billion), 2024-2030
Figure 3-11: Global - Gamma Delta T Cell Therapy Market Opportunity by 10% of Total Cell Therapy Market (US$ Billion), 2024-2030
Figure 4-1: Global - Gamma Delta T Cell Therapy Clinical Trials By Phase (Numbers), 2024 - 2030
Figure 4-2: Global - Gamma Delta T Cell Therapy Clinical Trials By Country (Numbers), 2024 - 2030
Figure 4-3: Global - Gamma Delta T Cell Therapy Clinical Trials By Company (Numbers), 2024 - 2030
Figure 4-4: Global - Gamma Delta T Cell Therapy Clinical Trials By Indication (Numbers), 2024
Figure 4-5: Global - Gamma Delta T Cell Therapy Clinical Trials By Priority Status (Numbers), 2024
Figure 6-1: Benefits of Gamma Delta T Cells in Leukemia
Figure 6-2: CD33CART Phase 1/2 (NCT03971799) Study - Initiation & Completion Year
Figure 6-3: CD33CART Phase 2 (NCT03971799) Study - Initiation & Completion Year
Figure 6-4: INB-100 Phase 1 (NCT03533816) Study - Initiation & Completion Year
Figure 6-5: Mechanism of Action of VGamma-9/CD123 Bispecific Antibody
Figure 6-6: Global - Estimated Leukemia Cases, 2024-2030
Figure 6-7: US - Estimated Leukemia Cases, 2024-2030
Figure 6-8: Europe - Estimated Leukemia Cases, 2024-2030
Figure 6-9: China - Estimated Leukemia Cases, 2024-2030
Figure 6-10: Japan - Estimated Leukemia Cases, 2024-2030
Figure 7-1: Role of Gamma Delta T Cells in Lung Cancer
Figure 7-2: KB-GDT-01 Phase 1 (NCT06069570) Study - Initiation & Completion Year
Figure 7-3: Global - Estimated Lung Cancer Cases, 2024-2030
Figure 7-4: US - Estimated Lung Cancer Cases, 2024-2030
Figure 7-5: Europe - Estimated Lung Cancer Cases, 2024-2030
Figure 7-6: China - Estimated Lung Cancer Cases, 2024-2030
Figure 7-7: Japan - Estimated Lung Cancer Cases, 2024-2030
Figure 8-1: Global - Estimated Breast Cancer Cases, 2024-2030
Figure 8-2: US - Estimated Breast Cancer Cases, 2024-2030
Figure 8-3: Europe - Estimated Breast Cancer Cases, 2024-2030
Figure 8-4: China - Estimated Breast Cancer Cases, 2024-2030
Figure 8-5: Japan - Estimated Breast Cancer Cases, 2024-2030
Figure 9-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 9-2: Mechanism Underlying B7-H3 Regulating Gamma-Delta T Cells Killing Colon Cancer Cells
Figure 9-3: PF-08046052 Phase I (NCT05983133) Study - Initiation & Completion Year
Figure 9-4: Global - Estimated Colorectal Cancer Cases, 2024-2030
Figure 9-5: US - Estimated Colorectal Cancer Cases, 2024-2030
Figure 9-6: Europe - Estimated Colorectal Cancer Cases, 2024-2030
Figure 9-7: China - Estimated Colorectal Cancer Cases, 2024-2030
Figure 9-8: Japan - Estimated Colorectal Cancer Cases, 2024-2030
Figure 10-1: Auspicious Outcomes Gamma Delta T Cell Therapy
Figure 10-2: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 10-3: Global - Estimated Pancreatic Cancer Cases, 2024-2030
Figure 10-4: US - Estimated Pancreatic Cancer Cases, 2024-2030
Figure 10-5: Europe - Estimated Pancreatic Cancer Cases, 2024-2030
Figure 10-6: China - Estimated Pancreatic Cancer Cases, 2024-2030
Figure 10-7: Japan - Estimated Pancreatic Cancer Cases, 2024-2030
Figure 11-1: ACE1831 Phase I (NCT05653271) Study - Initiation & Completion Year
Figure 11-2: ADI-001 Phase I (NCT04735471) Study - Initiation & Completion Year
Figure 11-3: Global - Estimated Lymphoma Cases, 2024-2030
Figure 11-4: US - Estimated Lymphoma Cases, 2024-2030
Figure 11-5: Europe - Estimated Lymphoma Cases, 2024-2030
Figure 11-6: China - Estimated Lymphoma Cases, 2024-2030
Figure 11-7: Japan - Estimated Lymphoma Cases, 2024-2030
Figure 12-1: DeltEx With Temozolomide (TMZ) Phase 1/2 (NCT05664243) Study - Initiation & Completion Year
Figure 12-2: IN8bio - Autologous (INB-400) & Allogeneic (INB-410) Candidates
Figure 12-3: Gamma-Delta T Cells Phase 1 (NCT04165941) Study - Initiation & Completion Year
Figure 12-4: Aflac-NBL-2002 Phase 1 (NCT05400603) Study - Initiation & Completion Year
Figure 12-5: Global - Estimated Brain Cancer Cases, 2024-2030
Figure 12-6: US - Estimated Brain Tumor Cases, 2024-2030
Figure 12-7: Europe - Estimated Brain Tumor Cases, 2024-2030
Figure 12-8: China - Estimated Brain Tumor Cases, 2024-2030
Figure 12-9: Japan - Estimated Brain Tumor Cases, 2024-2030
Figure 13-1: Acepodia Biotech Clinical Pipeline Insight
Figure 13-2: Pfizer & Lava Therapeutics Collaboration
Figure 13-3L: SGN-EGFRd2 Phase 1 (NCT05983133) Study - Initiation & Completion Year
Figure 13-4: Global - Estimated Head & Neck Cancer Cases, 2024-2030
Figure 13-5: US - Estimated Head & Neck Cancer Cases, 2024-2030
Figure 13-6: Europe - Estimated Head & Neck Cancer Cases, 2024-2030
Figure 13-7: China - Estimated Head & Neck Cancer Cases, 2024-2030
Figure 13-8: Japan - Estimated Head & Neck Cancer Cases, 2024-2030
Figure 14-1: ADI-001 Phase 1 (NCT06375993) Study - Initiation & Completion Year
Figure 14-2: Adicet Bio ADI-001 Fast Track Designation
Figure 14-3: ImCheck Therapeutics - Clinical Candidates Indications & Mode of Action Insights
Figure 14-4: ICT21 - Mechanism of Action
Figure 15-1: Gamma Delta T Cell Therapy Combinations
Figure 16-1: IN8bio - DeltEx DRI Auto
Figure 16-2: Diamond AI - Prediction Engine
Figure 16-3: Diamond AI - Immune Surveillance
Figure 16-4: Acepodia - Antibody-Cell Conjugation
Figure 16-5: Lava Therapeutics - Gammabody Platform
Figure 16-6: Adicet Bio - Gamma Delta Cell Platform
Figure 16-7: ADI-001 - Gamma Delta Cell Therapy
Figure 16-8: Century Therapeutics - Allo-Evasion
Figure 16-9: ViGenCell - ViRanger Platform
Figure 16-10: Legend Biotech - CAR-Gamma-Delta T Platform
Figure 16-11: Immatics - ACTallo-R Manufacturing Process
Figure 17-1: Global - Cancer Incidences & Mortality Rates (Billion), 2020 & 2040
Figure 17-2: Gamma Delta T Cells Favorable Market Parameters
Figure 17-3: Stages of Drug Development

Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030 Report Conclusions:

Number Of Gamma Delta T Cell Therapies In Trials: > 30 Therapies
US & China Dominating Clinical Trials Landscape: > 20 Therapies
Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase
Gamma Delta T Cell Therapy Future Market Opportunity By Different Cancers
Insight On Clinical Platforms for Evolving Gamma Delta T Cell Therapy: > 10 Platforms By Companies
Ongoing Clinical Research & Development Trends By Different Cancers
Insight On 12 Companies Developing Gamma Delta T Cell Therapies

After vicennium of futuristic T cells entrenched immunotherapy dominating the treatment landscape of cancer arena, there is a prerequisite to branch out cancer immunotherapy realm by developing other state-of-the-art therapies. But in spite of that, this led to discovery of other T cells receptors, such as gamma delta T cells, alpha-beta T cell and others. Consecutively, finding of gamma delta T cells based immunotherapy (also recognized as Yδ T cells), it was further pragmatic that developing gamma delta T cells based immunotherapies will aid to offer a innovatory treatment for cancer along with other disorders, including viral infections, autoimmune and inflammation.

With respect to KuicK Research statistics, the global clinical conduit of gamma delta T cells based immunotherapy comprises of 30 drugs (as of June 2024), several of which are in preclinical stage as well as majority of research and development along with technological advancement in in this sector is ongoing in the US and China region. Albeit, no drug has penetrated into the commercial market to treat cancer or other ailments; however, as soon as one drug will get approved will aid to launch other gamma delta T cells based immunotherapy into market and clenches potential to become a multimillionaire market in imminent.

One of the strategic prime movers that bestow to bourgeon the growth of gamma delta T cells based immunotherapy market is the rise in preclinical and clinical studies. Over the preceding decennium, the sphere of global gamma delta T cells based immunotherapy market has witnessed the development of several novel, innovative as well as advanced competitors. For instance, a clinical-stage biotechnology company in US, Acepodia Biotech has developed 2 contenders, ACE1708 as well as ACE2016 to treat solid tumor expressing PD-L1 accompanied with EGFR expressing tumors.

Coupled with this, the presences of various stakeholders in conjugation with investors from giant pharma companies accompanied with biotech companies, such as Bristol Myers Squibb, TC Biopharm, PersonGen BioTherapeutics, In8bio, Kiromic BioPharma, Immatics, Legend Biotech, Innate Pharma, Ever Supreme Bio Technology, Editas Medicine, CytoMed Therapeutics, Acepodia Biotech and other have bestowed to transform the treatment paradigm by developing up-to-the-minute gamma delta T cells based immunotherapy worldwide. Amid all these companies, PersonGen BioTherapeutics is the frontrunner in this segment as the company is developing 5 allogeneic UCAR- Yδ1 T cell therapy for the treatment of autoimmune, T cell malignancies and other solid tumors. The presences of giant pharmaceuticals aid to conduct multitudinous clinical trials in gamma delta T cells based immunotherapy space.

Just as importantly, an inclining market trend towards developing avant-garde global gamma delta T cells based immunotherapy, such as developing gamma-delta gene editing based immunotherapy, is gaining spotlight amid healthcare professionals. For instance, a biotech company based in Germany, Immatics has collaborated with Bristol Myers Squibb and Editas Medicine in order To syndicate gamma-delta T cell based adoptive cell therapies in addition to gene editing for the treatment of cancer.

Until now, no gamma delta T cells based immunotherapies has been approved in global market; nevertheless, it can be anticipated that a handful of gamma delta T cells therapies will be launched into the market in approaching 5 to 7 years due to the fact that many gamma delta T cells based immunotherapies have received FDA designations which aid to accelerate the approval process. For instance, ADI-001 has gained utmost breakthrough as it has received FDA fast track designation for the potential treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), in 2022, and relapsed/refractory class III or class IV lupus nephritis in June 2024. Overall, aforementioned illustrates clearly forecasts that the future of gamma delta T cells based immunotherapies will be propitious.

1. Introduction To Gamma Delta T Cell Therapy

1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview of Gamma Delta T Cell Therapy
1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies

2. Role of Gamma Delta T Cells in Cancer

2.1 Gamma Delta T Cells in Cancer Progression
2.2 Anti Tumor Activity of Gamma Delta T Cells
2.3 Adopted Approaches for Gamma Delta T Cell Therapy

3. Global Gamma Delta T Cell Therapy Market Overview

3.1 Current Market Scenario
3.2 Market Potential of Gamma Delta T Cell Therapy Market

4. Global Gamma Delta T Cell Therapy Clinical Trials Overview

4.1 By Phase
4.2 By Country
4.3 By Company
4.4 By Indication
4.5 By Priority Status

5. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase I/II
5.5 Phase II

6. Gamma Delta T Cell Therapy in Leukemia

6.1 Ongoing Clinical Research & Development Trends
6.2 Future Market Opportunity of Gamma Delta T Cells in Leukemia

7. Gamma Delta T Cell Therapy in Lung Cancer

7.1 Ongoing Clinical Research & Development Trends
7.2 Future Market Opportunity of Gamma Delta T Cell Therapy in Lung Cancer

8. Gamma Delta T Cells in Breast Cancer

8.1 Ongoing Clinical Research & Development Trends
8.2 Future Market Opportunity of Gamma Delta T Cell Therapy in Breast Cancer

9. Gamma Delta T Cells in Colorectal Cancer

9.1 Ongoing Clinical Research & Development Trends
9.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

10. Gamma Delta T Cells in Pancreatic Cancer

10.1 Ongoing Clinical Research & Development Trends
10.2 Future Market Potential of Gamma Delta Therapy in Pancreatic Cancer

11. Gamma Delta T Cells in Lymphoma

11.1 Ongoing Clinical Research & Development Trends
11.2 Future Outlook in Lymphoma

12. Gamma Delta T Cell Therapy in Brain Tumors

12.1 Research & Development in Brain Tumors
12.2 Future Outlook in Brain Tumors

13. Gamma Delta T Cell Therapy in Head & Neck Cancer

13.1 Research & Development in Head & Neck Cancer
13.2 Future Outlook in Head & Neck Cancer

14. Gamma Delta T Cell Therapy in Autoimmune, Inflammatory & Microbial Ailments

14.1 Research & Development in Autoimmune, Inflammatory & Microbial Ailments

15. Combination Methodologies for Gamma Delta T Cell Therapy

16. Platforms for Evolving Gamma Delta T Cell Therapy

17. Gamma Delta T Cell Therapy Market Dynamics

17.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
17.2 Gamma Delta T Cell Therapy Market: Challenges

18. Competitive Landscape

18.1 Acepodia
18.2 Adicet
18.3 Cytomed Therapeutics
18.4 Expression Therapeutics
18.5 Janssen Biotech
18.6 Gadeta
18.7 GammaDelta Therapeutics (Takeda)
18.8 IN8bio
18.9 Kiromic Biopharma
18.10 Lava Therapeutics
18.11 Regeneron Pharmaceuticals
18.12 TC Biopharm

ライセンス / 価格

PDF (Single User License)

USD 3,000 427,620円

その他のライセンス / 価格

PDF (Multi-User License)

USD 6,000 855,240円

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=142.54円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

お電話でのお問い合わせ

044-952-0102

( 土日・祝日を除く )

T細胞

がんのガンマ・デルタT細胞治療の世界市場：市場の機会と臨床試験の洞察（2030年）

Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030

目次

第1章 ガンマ・デルタT細胞治療のイントロダクション

第2章 ガンマ・デルタT細胞ががんに果たす役割

第3章 世界のガンマ・デルタT細胞治療市場概要

第4章 世界のガンマ・デルタT細胞治療の臨床試験の概要

第5章 世界のガンマ・デルタT細胞治療の臨床試験の洞察、企業、国、適応症、相別

第6章 白血病におけるガンマ・デルタT細胞治療

第7章 肺がんにおけるガンマ・デルタT細胞治療

第8章 乳がんにおけるガンマ・デルタT細胞

第9章 大腸がんにおけるガンマ・デルタT細胞

第10章 膵臓がんにおけるガンマ・デルタT細胞

第11章 リンパ腫におけるガンマ・デルタT細胞

第12章 脳腫瘍におけるガンマ・デルタT細胞治療

第13章 頭頸部がんにおけるガンマ・デルタT細胞治療

第14章 自己免疫疾患、炎症性疾患、微生物疾患におけるガンマ・デルタT細胞治療

第15章 ガンマ・デルタT細胞治療の併用療法

第16章 ガンマ・デルタT細胞治療の発展のためのプラットフォーム

第17章 ガンマ・デルタT細胞治療市場力学

第18章 競合情勢

List of Tables

List of Figures

Table of Contents

1. Introduction To Gamma Delta T Cell Therapy

2. Role of Gamma Delta T Cells in Cancer

3. Global Gamma Delta T Cell Therapy Market Overview

4. Global Gamma Delta T Cell Therapy Clinical Trials Overview

5. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

6. Gamma Delta T Cell Therapy in Leukemia

7. Gamma Delta T Cell Therapy in Lung Cancer

8. Gamma Delta T Cells in Breast Cancer

9. Gamma Delta T Cells in Colorectal Cancer

10. Gamma Delta T Cells in Pancreatic Cancer

11. Gamma Delta T Cells in Lymphoma

12. Gamma Delta T Cell Therapy in Brain Tumors

13. Gamma Delta T Cell Therapy in Head & Neck Cancer

14. Gamma Delta T Cell Therapy in Autoimmune, Inflammatory & Microbial Ailments

15. Combination Methodologies for Gamma Delta T Cell Therapy

16. Platforms for Evolving Gamma Delta T Cell Therapy

17. Gamma Delta T Cell Therapy Market Dynamics

18. Competitive Landscape

第1章ガンマ・デルタT細胞治療のイントロダクション

第2章ガンマ・デルタT細胞ががんに果たす役割

第3章世界のガンマ・デルタT細胞治療市場概要

第4章世界のガンマ・デルタT細胞治療の臨床試験の概要

第5章世界のガンマ・デルタT細胞治療の臨床試験の洞察、企業、国、適応症、相別

第6章白血病におけるガンマ・デルタT細胞治療

第7章肺がんにおけるガンマ・デルタT細胞治療

第8章乳がんにおけるガンマ・デルタT細胞

第9章大腸がんにおけるガンマ・デルタT細胞

第10章膵臓がんにおけるガンマ・デルタT細胞

第11章リンパ腫におけるガンマ・デルタT細胞

第12章脳腫瘍におけるガンマ・デルタT細胞治療

第13章頭頸部がんにおけるガンマ・デルタT細胞治療

第14章自己免疫疾患、炎症性疾患、微生物疾患におけるガンマ・デルタT細胞治療

第15章ガンマ・デルタT細胞治療の併用療法

第16章ガンマ・デルタT細胞治療の発展のためのプラットフォーム

第17章ガンマ・デルタT細胞治療市場力学

第18章競合情勢